Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey
Most clinicians agree knowing the Lp(a) level can improve risk assessment and patient engagement. Patients with premature or recurrent CVD events are most likely to be targeted for Lp(a) testing and for prescribing possible future Lp(a)-targeted therapies.
Authors
- Xingdi Hu
- Yihang Fan
- Jonathan H Ward
- Belinda Schludi
- Wenjun Fan
- Nathan D. Wong
Institutions
- Novartis (Switzerland) (CH)
- University of California, Irvine (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.ajpc.2025.101388
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01